ZGNX Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ZGNX — AI-powered stock analysis, price $26.68, MoonshotScore 71/100.
Price as of Jul 23, 2026 · Last analyzed: Jul 22, 2026Analyst Coverage for ZGNX: ZGNX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ZGNX against Healthcare peers across nine fundamental dimensions and assigns a relatively strong fundamental profile based on the underlying data.
ZGNX: 1/3 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
ZGNX Company Overview
Who Are ZGNX's Competitors?
ZGNX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | $473.09 | +0.11% | $121B | 99 |
| REGN Regeneron Pharmaceuticals, Inc. | $649.90 | -0.20% | $67.0B | 92 |
| ALNY Alnylam Pharmaceuticals, Inc. | $268.74 | +0.66% | $35.9B | 95 |
| RPRX Royalty Pharma plc | $59.02 | +0.50% | $25.4B | 81 |
| INCY Incyte Corporation | $116.69 | +0.78% | $23.3B | 99 |
| UTHR United Therapeutics Corporation | $527.07 | -1.63% | $23.0B | 99 |
| NBIX Neurocrine Biosciences, Inc. | $172.69 | -3.55% | $17.4B | 95 |
| EXEL Exelixis, Inc. | $55.65 | +1.22% | $14.0B | 99 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are the Key Risks for ZGNX?
- Negative return on equity (-82.9%) — the business is not currently generating profit on shareholder capital.
How ZGNX Is Valued
Relative to its peer group, ZGNX's quantitative score of 71/100 is below the peer average of 93/100.
Company Profile
ZGNX operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Emeryville, US. The company is led by CEO Stephen Farr. ZGNX has traded publicly since 2010.
ROE -83%Key Financial Metrics
Return on equity for ZGNX stands at -82.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -48.5%, showing how much profit it generates from its asset base. A current ratio of 3.63 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -15.9%, the inverse of the P/E and a quick read on earnings relative to price.
ZGNX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
ZGNX Latest News
-
Stocks That Hit 52-Week Lows On Thursday
· Feb 27, 2020
-
Stocks That Hit 52-Week Lows On Wednesday
· Feb 26, 2020
-
Stocks That Hit 52-Week Highs On Friday
· Jan 17, 2020
-
44 Biggest Movers From Yesterday
· Jul 13, 2018
ZGNX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ZGNX.
Price Targets
Wall Street price target analysis for ZGNX.
ZGNX MoonshotScore
What does this score mean?
The MoonshotScore rates ZGNX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
What Investors Ask About ZGNX (ZGNX)
What does the AI Score mean for ZGNX?
ZGNX holds an AI Score of 71/100 (Grade: A). This is an educational research signal, not a buy or sell recommendation. ZGNX AI Score: 71/100 (Grade: A). This is an educational research signal, not a buy or sell recommendation.
What are the key factors to evaluate for ZGNX?
Evaluate ZGNX on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does ZGNX data refresh on this page?
ZGNX prices refresh on page view and on a rolling daily schedule; the last-updated date appears near the top of this page. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ZGNX's recent stock price performance?
ZGNX moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ZGNX overvalued or undervalued right now?
ZGNX has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ZGNX before investing?
Before investing in ZGNX, research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding ZGNX to a portfolio?
No dossier-level strength is on record for ZGNX yet — start from the MoonshotScore factor breakdown and the Financials tab on this page. Weigh rewards against risks and diversify. Not financial advice.
Can I buy fractional shares of ZGNX?
Yes, most major brokerages offer fractional shares of ZGNX with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ZGNX's earnings and financial reports?
ZGNX reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for ZGNX earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.